Abstract:

Purpose: The effectiveness and tolerability of fulvestrant therapy after hormone therapy has been first assessed in postmenopausal patients with positive breast cancer.  Method: Metastatic breast cancer patients treated between 2014-2017 in the two units involved in the study were examined retrospectively. The study included patients who were given a fulvestrant 500 mg intramuscular treatment every 28 days, and the response assessment was made every 2 months until progress.  In total, 48 patients were involved in the study. The majority of patients in the first round of treatment used an aromatase inhibitor (77) . In 25% of patients, visual metastasis was found. The average non-progressive survival and median survival are 6 months (95% CI, 4.5-7,5) and 26.6 months (95% Journal of Human Rhythm 2019;5(1):13-22. The boy and ark. The effectiveness and tolerability of fulvestrant therapy in metastatic hormone positive breast cancer was 14 CI, 19,5-33,6. In 12.5 percent of patients, partial response was observed and in 41.7 percent a stable disease was observed. The most frequently side effects were mild-mediate, injection area pain (20,8 percent), dyspepsia (16,6 percent) and myalgia (16,6 percent).  The result: Fulvestrant postmenopausal hormone positive has been shown to be quite effective and tolerable in patients with breast cancer after the first time hormone therapy progressed.

Keywords: